Cargando…

Volumetric intensity-modulated Arc (RapidArc) therapy for primary hepatocellular carcinoma: comparison with intensity-modulated radiotherapy and 3-D conformal radiotherapy

BACKGROUND: To compare the RapidArc plan for primary hepatocellular carcinoma (HCC) with 3-D conformal radiotherapy (3DCRT) and intensity-modulated radiotherapy (IMRT) plans using dosimetric analysis. METHODS: Nine patients with unresectable HCC were enrolled in this study. Dosimetric values for Rap...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuo, Yu-Cheng, Chiu, Ying-Ming, Shih, Wen-Pin, Yu, Hsiao-Wei, Chen, Chia-Wen, Wong, Pei-Fong, Lin, Wei-Chan, Hwang, Jeng-Jong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3138395/
https://www.ncbi.nlm.nih.gov/pubmed/21693003
http://dx.doi.org/10.1186/1748-717X-6-76
_version_ 1782208378038124544
author Kuo, Yu-Cheng
Chiu, Ying-Ming
Shih, Wen-Pin
Yu, Hsiao-Wei
Chen, Chia-Wen
Wong, Pei-Fong
Lin, Wei-Chan
Hwang, Jeng-Jong
author_facet Kuo, Yu-Cheng
Chiu, Ying-Ming
Shih, Wen-Pin
Yu, Hsiao-Wei
Chen, Chia-Wen
Wong, Pei-Fong
Lin, Wei-Chan
Hwang, Jeng-Jong
author_sort Kuo, Yu-Cheng
collection PubMed
description BACKGROUND: To compare the RapidArc plan for primary hepatocellular carcinoma (HCC) with 3-D conformal radiotherapy (3DCRT) and intensity-modulated radiotherapy (IMRT) plans using dosimetric analysis. METHODS: Nine patients with unresectable HCC were enrolled in this study. Dosimetric values for RapidArc, IMRT, and 3DCRT were calculated for total doses of 45~50.4 Gy using 1.8 Gy/day. The parameters included the conformal index (CI), homogeneity index (HI), and hot spot (V(107%)) for the planned target volume (PTV) as well as the monitor units (MUs) for plan efficiency, the mean dose (D(mean)) for the organs at risk (OAR) and the maximal dose at 1% volume (D(1%)) for the spinal cord. The percentage of the normal liver volume receiving ≥ 40, > 30, > 20, and > 10 Gy (V(40 Gy), V(30 Gy), V(20 Gy), and V(10 Gy)) and the normal tissue complication probability (NTCP) were also evaluated to determine liver toxicity. RESULTS: All three methods achieved comparable homogeneity for the PTV. RapidArc achieved significantly better CI and V(107% )values than IMRT or 3DCRT (p < 0.05). The MUs were significantly lower for RapidArc (323.8 ± 60.7) and 3DCRT (322.3 ± 28.6) than for IMRT (1165.4 ± 170.7) (p < 0.001). IMRT achieved a significantly lower D(mean )of the normal liver than did 3DCRT or RapidArc (p = 0.001). 3DCRT had higher V(40 Gy )and V(30 Gy )values for the normal liver than did RapidArc or IMRT. Although the V(10 Gy )to the normal liver was higher with RapidArc (75.8 ± 13.1%) than with 3DCRT or IMRT (60.5 ± 10.2% and 57.2 ± 10.0%, respectively; p < 0.01), the NTCP did not differ significantly between RapidArc (4.38 ± 2.69) and IMRT (3.98 ± 3.00) and both were better than 3DCRT (7.57 ± 4.36) (p = 0.02). CONCLUSIONS: RapidArc provided favorable tumor coverage compared with IMRT or 3DCRT, but RapidArc is not superior to IMRT in terms of liver protection. Further studies are needed to establish treatment outcome differences between the three approaches.
format Online
Article
Text
id pubmed-3138395
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-31383952011-07-19 Volumetric intensity-modulated Arc (RapidArc) therapy for primary hepatocellular carcinoma: comparison with intensity-modulated radiotherapy and 3-D conformal radiotherapy Kuo, Yu-Cheng Chiu, Ying-Ming Shih, Wen-Pin Yu, Hsiao-Wei Chen, Chia-Wen Wong, Pei-Fong Lin, Wei-Chan Hwang, Jeng-Jong Radiat Oncol Research BACKGROUND: To compare the RapidArc plan for primary hepatocellular carcinoma (HCC) with 3-D conformal radiotherapy (3DCRT) and intensity-modulated radiotherapy (IMRT) plans using dosimetric analysis. METHODS: Nine patients with unresectable HCC were enrolled in this study. Dosimetric values for RapidArc, IMRT, and 3DCRT were calculated for total doses of 45~50.4 Gy using 1.8 Gy/day. The parameters included the conformal index (CI), homogeneity index (HI), and hot spot (V(107%)) for the planned target volume (PTV) as well as the monitor units (MUs) for plan efficiency, the mean dose (D(mean)) for the organs at risk (OAR) and the maximal dose at 1% volume (D(1%)) for the spinal cord. The percentage of the normal liver volume receiving ≥ 40, > 30, > 20, and > 10 Gy (V(40 Gy), V(30 Gy), V(20 Gy), and V(10 Gy)) and the normal tissue complication probability (NTCP) were also evaluated to determine liver toxicity. RESULTS: All three methods achieved comparable homogeneity for the PTV. RapidArc achieved significantly better CI and V(107% )values than IMRT or 3DCRT (p < 0.05). The MUs were significantly lower for RapidArc (323.8 ± 60.7) and 3DCRT (322.3 ± 28.6) than for IMRT (1165.4 ± 170.7) (p < 0.001). IMRT achieved a significantly lower D(mean )of the normal liver than did 3DCRT or RapidArc (p = 0.001). 3DCRT had higher V(40 Gy )and V(30 Gy )values for the normal liver than did RapidArc or IMRT. Although the V(10 Gy )to the normal liver was higher with RapidArc (75.8 ± 13.1%) than with 3DCRT or IMRT (60.5 ± 10.2% and 57.2 ± 10.0%, respectively; p < 0.01), the NTCP did not differ significantly between RapidArc (4.38 ± 2.69) and IMRT (3.98 ± 3.00) and both were better than 3DCRT (7.57 ± 4.36) (p = 0.02). CONCLUSIONS: RapidArc provided favorable tumor coverage compared with IMRT or 3DCRT, but RapidArc is not superior to IMRT in terms of liver protection. Further studies are needed to establish treatment outcome differences between the three approaches. BioMed Central 2011-06-21 /pmc/articles/PMC3138395/ /pubmed/21693003 http://dx.doi.org/10.1186/1748-717X-6-76 Text en Copyright ©2011 Kuo et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Kuo, Yu-Cheng
Chiu, Ying-Ming
Shih, Wen-Pin
Yu, Hsiao-Wei
Chen, Chia-Wen
Wong, Pei-Fong
Lin, Wei-Chan
Hwang, Jeng-Jong
Volumetric intensity-modulated Arc (RapidArc) therapy for primary hepatocellular carcinoma: comparison with intensity-modulated radiotherapy and 3-D conformal radiotherapy
title Volumetric intensity-modulated Arc (RapidArc) therapy for primary hepatocellular carcinoma: comparison with intensity-modulated radiotherapy and 3-D conformal radiotherapy
title_full Volumetric intensity-modulated Arc (RapidArc) therapy for primary hepatocellular carcinoma: comparison with intensity-modulated radiotherapy and 3-D conformal radiotherapy
title_fullStr Volumetric intensity-modulated Arc (RapidArc) therapy for primary hepatocellular carcinoma: comparison with intensity-modulated radiotherapy and 3-D conformal radiotherapy
title_full_unstemmed Volumetric intensity-modulated Arc (RapidArc) therapy for primary hepatocellular carcinoma: comparison with intensity-modulated radiotherapy and 3-D conformal radiotherapy
title_short Volumetric intensity-modulated Arc (RapidArc) therapy for primary hepatocellular carcinoma: comparison with intensity-modulated radiotherapy and 3-D conformal radiotherapy
title_sort volumetric intensity-modulated arc (rapidarc) therapy for primary hepatocellular carcinoma: comparison with intensity-modulated radiotherapy and 3-d conformal radiotherapy
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3138395/
https://www.ncbi.nlm.nih.gov/pubmed/21693003
http://dx.doi.org/10.1186/1748-717X-6-76
work_keys_str_mv AT kuoyucheng volumetricintensitymodulatedarcrapidarctherapyforprimaryhepatocellularcarcinomacomparisonwithintensitymodulatedradiotherapyand3dconformalradiotherapy
AT chiuyingming volumetricintensitymodulatedarcrapidarctherapyforprimaryhepatocellularcarcinomacomparisonwithintensitymodulatedradiotherapyand3dconformalradiotherapy
AT shihwenpin volumetricintensitymodulatedarcrapidarctherapyforprimaryhepatocellularcarcinomacomparisonwithintensitymodulatedradiotherapyand3dconformalradiotherapy
AT yuhsiaowei volumetricintensitymodulatedarcrapidarctherapyforprimaryhepatocellularcarcinomacomparisonwithintensitymodulatedradiotherapyand3dconformalradiotherapy
AT chenchiawen volumetricintensitymodulatedarcrapidarctherapyforprimaryhepatocellularcarcinomacomparisonwithintensitymodulatedradiotherapyand3dconformalradiotherapy
AT wongpeifong volumetricintensitymodulatedarcrapidarctherapyforprimaryhepatocellularcarcinomacomparisonwithintensitymodulatedradiotherapyand3dconformalradiotherapy
AT linweichan volumetricintensitymodulatedarcrapidarctherapyforprimaryhepatocellularcarcinomacomparisonwithintensitymodulatedradiotherapyand3dconformalradiotherapy
AT hwangjengjong volumetricintensitymodulatedarcrapidarctherapyforprimaryhepatocellularcarcinomacomparisonwithintensitymodulatedradiotherapyand3dconformalradiotherapy